Effectiveness of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

1,160

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Acute Myocardial Infarction (AMI)

Interventions

DRUG

Tafolecimab

450mg of tafolecimab (150mg each one) was injected subcutaneously before primary PCI and then every month till totally 12 months.

Trial Locations (1)

The affiliated hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors

lead

The Affiliated Hospital of Xuzhou Medical University

OTHER